Premium
Treatment of patients with hepatitis C and normal serum aminotransferase levels
Author(s) -
Bacon Bruce R.
Publication year - 2002
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.1840360723
Subject(s) - medicine , ribavirin , hepatology , gastroenterology , cirrhosis , liver biopsy , fibrosis , hepatitis c virus , hepatitis c , interferon , alanine transaminase , alanine aminotransferase , liver disease , viral hepatitis , biopsy , immunology , virus
Abstract Approximately 30% of patients with chronic hepatitis C have normal serum alanine aminotransferase (ALT) levels and another 40% have ALT levels that are less than twice the upper limit of the normal range. Most patients with normal ALT levels have mild degrees of inflammation with mild or no fibrosis, and the rate of disease progression is reduced compared with that in patients with elevated ALT levels. Some patients with normal ALT levels have advanced fibrosis and cirrhosis on liver biopsy. Treatment of patients with normal ALT levels with either interferon monotherapy or interferon/ribavirin combination therapy has shown sustained virological response (SVR) rates that are equivalent to those achieved for patients with elevated ALT levels. Thus, patients with chronic hepatitis C should not be excluded from therapy based on ALT levels alone. The decision to initiate therapy with interferon and ribavirin should be based on a combination of factors independent of ALT levels including amount of fibrosis on liver biopsy, hepatitis C virus (HCV) genotype and viral level, patient age and motivation, and co‐morbid illness, and the presence of other complicating conditions. (H EPATOLOGY 2002;36:S179–S184).